fluorescein sodium and benoxinate hydrochloride solution/ drops
bausch & lomb incorporated - benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303), fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir) - benoxinate hydrochloride 4 mg in 1 ml - for procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent such as tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures. known hypersensitivity to any component of this product. prolonged use of a topical ocular anesthetic is not recommended. it may produce permanent corneal opacification with accompanying visual loss.
altafluor- fluorescein sodium and benoxinate hydrochloride solution
altaire pharmaceuticals inc. - benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303), fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir) - benoxinate hydrochloride 4 mg in 1 ml - altafluor benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is indicated for ophthalmic procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. altafluor benox is contraindicated in patients with known hypersensitivity to any component of this product. risk summary there are no available data on the use of altafluor benox in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. altafluor benox should be given to a pregnant woman only if clearly needed. risk summary there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of altafluor benox, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for altafluor benox a
fluorescein sodium and benoxinate hydrochloride solution/ drops
bausch & lomb incorporated - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product. risk summary there are no available data on the use of fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% should be given to a pregnant woman only if clearly needed. risk summary there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of fluorescein sodium and beno
fluorescein sodium and benoxinate hydrochloride solution/ drops
oceanside pharmaceuticals - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product. risk summary there are no available data on the use of fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% should be given to a pregnant woman only if clearly needed. risk summary there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of fluorescein sodium and beno
fluorescein sodium and benoxinate hydrochloride solution/ drops
bausch & lomb americas inc. - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product. risk summary there are no available data on the use of fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. fluorescein sodium and benoxinate hydrochloride ophthalmic solution, 0.3%/0.4% should be given to a pregnant woman only if clearly needed. risk summary there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of fluorescein sodium and beno
flurox (fluorescein sodium 2.5mg (0.25%), benoxinate hydrochloride 4mg- 0.4% solution
ocusoft, inc. - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - flourescein sodium and benoxinate hydrochloride opthalmic solution usp, 0.25%/0.4% is a disclosing agent with rapid anesthetic action of short duration. fluorescein sodium is represented by the following structural formula: chemical name: spiro [isobenzofuran-1 (3h ),9'-[9h ] xanthene]-3-one, 3',6' dihydroxy, disodium salt. benoxinate hydrochloride is represented by the following structural formula: chemical name: 2-(diethylamino) ethyl 4-amino-3butoxybenzoate monohydrochloride. for procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent such as tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures. known hypersensitivity to any component of this product.
altafluor- fluorescein sodium and benoxinate hydrochloride solution
altaire pharmaceuticals inc. - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - altafluor benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is indicated for ophthalmic procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. altafluor benox is contraindicated in patients with known hypersensitivity to any component of this product. risk summary there are no available data on the use of altafluor benox in pregnant women to inform any drug associated risk. adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. altafluor benox should be given to a pregnant woman only if clearly needed. risk summary there are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of altafluor benox, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for altafluor benox a
minims benoxinate hydrochloride 0.4% drops
chauvin pharmaceuticals limited - benoxinate hydrochloride - drops - .4% - benoxinate hydrochloride .4% - local anesthetics
fluress- fluorescein sodium and benoxinate hydrochloride solution/ drops
akorn, inc. - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir), benoxinate hydrochloride (unii: 0ve4u49k15) (benoxinate - unii:axq0jym303) - for procedures requiring a disclosing agent in combination with an anesthetic agent such as tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures. known hypersensitivity to any component of this product.
fluorescein sodium & benoxinate hydrochloride ophthalmic solution, usp
bausch & lomb inc - fluorescein sodium; benoxinate hydrochloride - solution - 0.25%; 0.4% - fluorescein sodium 0.25%; benoxinate hydrochloride 0.4% - local anesthetics